VanEck Associates’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $227M | Buy |
2,624,926
+13,948
| +0.5% | +$1.34M | 0.17% | 108 |
|
|
2025
Q4 | $251M | Buy |
2,610,978
+3,487
| +0.1% | +$339K | 0.21% | 99 |
|
|
2025
Q3 | $248M | Buy |
2,607,491
+17,328
| +0.7% | +$1.59M | 0.23% | 94 |
|
|
2025
Q2 | $226M | Buy |
2,590,163
+1,641
| +0.1% | +$139K | 0.26% | 86 |
|
|
2025
Q1 | $233M | Sell |
2,588,522
-9,628
| -0.4% | -$862K | 0.3% | 85 |
|
|
2024
Q4 | $208M | Buy |
2,598,150
+2,476,935
| +2,043% | +$214M | 0.27% | 92 |
|
|
2024
Q3 | $11.2M | Sell |
121,215
-2,189,492
| -95% | -$184M | 0.01% | 422 |
|
|
2024
Q2 | $182M | Sell |
2,310,707
-2,261,138
| -49% | -$185M | 0.26% | 101 |
|
|
2024
Q1 | $398M | Buy |
4,571,845
+432,484
| +10% | +$36.9M | 0.6% | 49 |
|
|
2023
Q4 | $341M | Buy |
4,139,361
+553,173
| +15% | +$42.2M | 0.62% | 59 |
|
|
2023
Q3 | $281M | Buy |
3,586,188
+510,020
| +17% | +$42.7M | 0.62% | 52 |
|
|
2023
Q2 | $271M | Buy |
3,076,168
+416,140
| +16% | +$35.8M | 0.59% | 49 |
|
|
2023
Q1 | $214M | Buy |
2,660,028
+450,953
| +20% | +$36.8M | 0.49% | 50 |
|
|
2022
Q4 | $172M | Buy |
2,209,075
+195,950
| +10% | +$15.9M | 0.44% | 57 |
|
|
2022
Q3 | $163M | Buy |
2,013,125
+159,915
| +9% | +$14.4M | 0.48% | 55 |
|
|
2022
Q2 | $166M | Buy |
1,853,210
+2,855
| +0.2% | +$289K | 0.44% | 60 |
|
|
2022
Q1 | $205M | Buy |
1,850,355
+280,980
| +18% | +$29.7M | 0.42% | 56 |
|
|
2021
Q4 | $162M | Buy |
1,569,375
+133,871
| +9% | +$15.5M | 0.38% | 80 |
|
|
2021
Q3 | $180M | Buy |
1,435,504
+49,251
| +4% | +$6.37M | 0.45% | 59 |
|
|
2021
Q2 | $172M | Buy |
1,386,253
+235,948
| +21% | +$29.6M | 0.41% | 63 |
|
|
2021
Q1 | $136M | Buy |
1,150,305
+178,308
| +18% | +$20.9M | 0.37% | 70 |
|
|
2020
Q4 | $114M | Buy |
971,997
+51,473
| +6% | +$5.67M | 0.33% | 68 |
|
|
2020
Q3 | $95.7M | Sell |
920,524
-43,766
| -5% | -$4.4M | 0.3% | 61 |
|
|
2020
Q2 | $88.4M | Buy |
964,290
+145,445
| +18% | +$13.9M | 0.31% | 66 |
|
|
2020
Q1 | $73.8M | Buy |
818,845
+10,557
| +1% | +$1.12M | 0.38% | 60 |
|
|
2019
Q4 | $91.7M | Buy |
808,288
+122,513
| +18% | +$13.4M | 0.35% | 65 |
|
|
2019
Q3 | $74.5M | Buy |
685,775
+42,736
| +7% | +$4.46M | 0.35% | 54 |
|
|
2019
Q2 | $62.6M | Buy |
643,039
+32,111
| +5% | +$2.93M | 0.3% | 69 |
|
|
2019
Q1 | $55.6M | Buy |
610,928
+82,643
| +16% | +$7.4M | 0.27% | 86 |
|
|
2018
Q4 | $48.1M | Buy |
528,285
+42,653
| +9% | +$3.99M | 0.24% | 76 |
|
|
2018
Q3 | $47.8M | Buy |
485,632
+547
| +0.1% | +$50.6K | 0.23% | 100 |
|
|
2018
Q2 | $41.5M | Buy |
485,085
+51,332
| +12% | +$4.29M | 0.19% | 108 |
|
|
2018
Q1 | $34.8M | Buy |
433,753
+40,236
| +10% | +$3.32M | 0.17% | 120 |
|
|
2017
Q4 | $31.8M | Buy |
393,517
+10,365
| +3% | +$830K | 0.16% | 145 |
|
|
2017
Q3 | $29.8M | Buy |
383,152
+207,584
| +118% | +$17.2M | 0.15% | 147 |
|
|
2017
Q2 | $15.6M | Buy |
175,568
+8,064
| +5% | +$680K | 0.09% | 180 |
|
|
2017
Q1 | $13.5M | Buy |
167,504
+17,205
| +11% | +$1.34M | 0.06% | 203 |
|
|
2016
Q4 | $10.7M | Buy |
+150,299
| New | +$11.8M | 0.05% | 215 |
|
|
2013
Q4 | – | Sell |
-339,062
| Closed | -$18.1M | – | 690 |
|
|
2013
Q3 | $18.1M | Buy |
+339,062
| New | +$18.2M | 0.09% | 130 |
|
Other funds holding MDT
VCM
VPM
VanEck Associates's MDT Position: Q1 2026 in Review
VanEck Associates increased its Medtronic (MDT) stake by 0.53% in Q1 2026, buying an estimated $1.34M and bringing the position to 2,624,926 shares worth $227M. The position accounts for 0.17% of the portfolio, ranked #108.
VanEck Associates first reported a position in MDT in Q3 2013 and has held it in 39 quarters since. The position peaked at $398M in Q1 2024. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.
- VanEck Associates held 2,624,926 shares of Medtronic worth $227M as of Q1 2026.
- VanEck Associates bought 13,948 Medtronic shares in Q1 2026, an estimated $1.34M.
- Medtronic made up 0.17% of VanEck Associates's portfolio in Q1 2026, its #108 holding.
- VanEck Associates first reported a position in Medtronic in Q3 2013 and has held it in 39 quarters since.
- VanEck Associates's Medtronic position peaked at $398M in Q1 2024.
- 2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.